{"product_id":"amicusrx-pestle-analysis","title":"Amicus Therapeutics PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, regulatory pressures, and rapid biotech innovation are shaping Amicus Therapeutics’ strategic outlook—our concise PESTLE highlights risks and opportunities you can act on immediately; purchase the full analysis for a complete, editable report that accelerates investment and strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal drug pricing legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Inflation Reduction Act’s Medicare drug price negotiation, set to affect select high-spend drugs from 2026, pressures orphan drug pricing and forces Amicus to adapt pricing strategies as U.S. government seeks roughly $100+ billion savings over a decade; globally, 2024–25 moves in EU and UK cost-containment initiatives and growing payer scrutiny heighten reimbursement risk, making political pressure a key threat to Amicus’s long-term revenue stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational trade and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a global biotech, Amicus depends on stable trade to supply Galafold (2024 revenue for Fabry therapies ~ $370m reported across the company) and Pombiliti into EU and Asian markets; 2023–25 regional launches face risk from tariff shifts and geopolitical tensions that could disrupt cold-chain supply and delay market entry by 6–12 months. Strong diplomatic ties and local regulatory engagement are vital to sustain international growth targets through 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment funding for rare diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical support for NIH and rare disease grants directly fuels Amicus Therapeutics’ early lysosomal storage disorder pipeline; NIH awarded roughly $32.5 billion in FY2024, with rare disease initiatives receiving targeted increases that benefit early-stage research funding. Legislative shifts toward rare disease advocacy affect public-private partnership opportunities and grant availability, while specialized tax credits and Orphan Drug incentives—contributing millions in R\u0026amp;D offsets—favor Amicus when policymakers prioritize high-need, low-prevalence conditions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare reform initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOngoing debates over universal healthcare and changes to the Affordable Care Act shape coverage for high-cost biotech treatments; in 2024 roughly 10% of US adults remained uninsured, affecting affordability for Amicus Therapeutics' therapies like migalastat (marketed revenues: $185m in 2024) and investigational programs.\u003c\/p\u003e\n\u003cp\u003ePolitical shifts that expand or restrict access to specialty care directly change Amicus' addressable market—Medicare\/Medicaid policy changes could alter reimbursements for ~30% of rare disease patients.\u003c\/p\u003e\n\u003cp\u003eAmicus must engage in policy advocacy to protect rare disease coverage across payer frameworks; in 2025 the company allocated increased lobbying and patient-support funding to sustain access and reimbursement efforts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUninsured ~10% (2024)\u003c\/li\u003e\n\u003cli\u003eMigalastat revenues ~$185m (2024)\u003c\/li\u003e\n\u003cli\u003e~30% patients affected by Medicare\/Medicaid policy\u003c\/li\u003e\n\u003cli\u003eIncreased 2025 advocacy and patient-support funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory agency leadership and policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChanges in FDA and EMA leadership can alter approval criteria and review timelines for gene therapies and enzyme replacements; under FDA Commissioner Robert Califf initial 2023–2025 guidance, median FDA review time for biologics remained ~10 months, but accelerated pathways rose by 12% in 2024.\u003c\/p\u003e\n\u003cp\u003ePolitical appointments influence regulatory risk tolerance and surrogate endpoint acceptance; FDA expedited approvals using surrogate endpoints accounted for ~28% of oncology\/rare disease approvals in 2024.\u003c\/p\u003e\n\u003cp\u003eAmicus closely monitors leadership shifts and guidance updates to align clinical development, aiming to preserve timelines and maximize chances for accelerated pathways for therapies like migalastat and pipeline candidates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedian FDA biologics review ~10 months (2023–2025)\u003c\/li\u003e\n\u003cli\u003eAccelerated\/expedited pathway use +12% in 2024\u003c\/li\u003e\n\u003cli\u003eSurrogate-endpoint approvals ~28% in 2024\u003c\/li\u003e\n\u003cli\u003eAmicus adjusts protocols to match evolving guidance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmicus faces pricing pressure, supply delays and access limits despite R\u0026amp;D support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedicare drug negotiation (IRA) and 2024–25 EU\/UK cost controls heighten reimbursement risk for Amicus, threatening orphan pricing and long-term revenue; Galafold\/Pombiliti supply and launches face 6–12 month delay risks from trade\/geopolitical issues; NIH rare-disease funding (~$32.5B FY2024) and Orphan incentives support R\u0026amp;D, while ~10% US uninsured and ~30% Medicare\/Medicaid exposure constrain access; FDA median biologics review ~10 months (2023–25).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH budget\u003c\/td\u003e\n\u003ctd\u003e$32.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMigalastat revenue\u003c\/td\u003e\n\u003ctd\u003e$185M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFabry therapies revenue\u003c\/td\u003e\n\u003ctd\u003e~$370M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUninsured US adults\u003c\/td\u003e\n\u003ctd\u003e~10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare\/Medicaid patient share\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA median biologics review\u003c\/td\u003e\n\u003ctd\u003e~10 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Amicus Therapeutics across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to inform strategy, risk management, and investor communications, delivered in clean, report-ready formatting and tailored examples for executives and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Amicus Therapeutics' PESTLE into a concise, shareable brief that highlights regulatory, market, and technological risks for quick use in meetings or presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost of capital and interest rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLate 2025's macro backdrop—with the US 10-year Treasury around 4.5% and average prime lending rates near 8%—raises Amicus Therapeutics' borrowing costs for capital-intensive R\u0026amp;D and manufacturing scale-up. Higher rates increase debt service, which could constrain aggressive clinical programs or acquisitions by raising financing costs and lowering NPV of projects. Amicus must preserve liquidity—cash, undrawn credit lines, and a debt-to-equity profile—to sustain commercialization and pipeline milestones amid rate volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWith roughly 40% of 2024 revenue sourced outside the US, Amicus faces meaningful exposure to USD\/EUR and USD\/JPY swings; a 5% USD appreciation could cut repatriated revenue by ~2% of total sales, pressuring 2025 margins. Currency headwinds in 2024 reduced operating income by an estimated $25–35m, underscoring the need for active hedging and natural currency offsets. Economic instability in key EU and Japan markets adds forecasting volatility and reporting complexity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary pressures on R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising costs for lab supplies, specialized talent, and clinical-trial management have pressured biotech margins; US CPI-driven medical supply inflation rose ~6% y\/y in 2024, increasing Amicus’s input costs and potentially widening operating losses if uncompensated.\u003c\/p\u003e\n\u003cp\u003eInflation permeates the biotech supply chain—from raw materials to cold-chain logistics—where global freight rates and cold-storage costs jumped ~12%–18% in 2023–24, raising per-patient trial and manufacturing expenses for biologics.\u003c\/p\u003e\n\u003cp\u003eTo protect its path to sustained profitability, Amicus must pursue cost-efficiency measures—process optimization, strategic supplier contracts, and targeted outsourcing—which a 2024 industry benchmarking study shows can cut unit costs 8%–15% within 12–18 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer reimbursement and affordability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePayer reimbursement pressures force stricter cost-benefit scrutiny for orphan drugs; U.S. specialty drug spend fell to 49% of total drug spend growth in 2024, increasing payer demand for demonstrable value for Amicus’s high-priced therapies.\u003c\/p\u003e\n\u003cp\u003eAmicus must justify premium pricing to recoup \u0026gt;$1 billion typical rare-disease R\u0026amp;D costs per approved asset, or face rejection or steep discounting by Medicare\/Medicaid and private plans.\u003c\/p\u003e\n\u003cp\u003eEconomic downturns raise utilization management and patient cost-sharing — 2024 surveys showed 27% of patients delayed specialty meds due to cost — risking adherence and revenue for Amicus.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePayer scrutiny rising as specialty drugs drive spending.\u003c\/li\u003e\n\u003cli\u003eNeed to demonstrate value vs. \u0026gt;$1B R\u0026amp;D per asset.\u003c\/li\u003e\n\u003cli\u003e27% patients delayed therapy in 2024 due to costs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestment climate for biotechnology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe strength of equity markets and biotech investor sentiment directly affects Amicus Therapeutics ability to raise secondary capital; biotech sector ETFs rose ~28% in 2023 while 2024 saw volatility, impacting financings for mid-cap names like Amicus (market cap ~2.5–3.5B in 2024–25).\u003c\/p\u003e\n\u003cp\u003eBullish healthcare markets ease funding for costly gene therapy programs, whereas recessions trigger flight to safety, shrinking venture\/institutional flows to mid-cap biotech.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEquity-market sensitivity: biotech ETF moves ±20–30% alter financing windows\u003c\/li\u003e\n\u003cli\u003eMarket cap reference: Amicus ~2.5–3.5B (2024–25)\u003c\/li\u003e\n\u003cli\u003eFunding risk: economic downturns reduce venture\/institutional capital availability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising rates, FX losses and cost inflation squeeze Amicus’s margins and growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising rates (US 10y ~4.5%, prime ~8% in late 2025) lift Amicus’s funding costs, squeezing NPV of R\u0026amp;D and making liquidity preservation critical; 2024 FX losses ~$25–35m highlight currency exposure (~40% revenue ex‑US) where a 5% USD gain could cut ~2% of sales. Inflation and supply\/logistics cost inflation (medical supplies +6% y\/y; freight\/cold chain +12–18% in 2023–24) raise per‑patient costs; payer pressure and patient copay delays (27% delayed specialty meds in 2024) threaten pricing power and uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023–25\/2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS 10‑yr \/ prime\u003c\/td\u003e\n\u003ctd\u003e~4.5% \/ ~8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX impact (2024)\u003c\/td\u003e\n\u003ctd\u003e$25–35m loss\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue ex‑US\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical supply inflation\u003c\/td\u003e\n\u003ctd\u003e+6% y\/y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFreight \/ cold chain\u003c\/td\u003e\n\u003ctd\u003e+12–18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients delaying specialty meds\u003c\/td\u003e\n\u003ctd\u003e27%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmicus market cap (2024–25)\u003c\/td\u003e\n\u003ctd\u003e~$2.5–3.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAmicus Therapeutics PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Amicus Therapeutics PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategy or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751721283961,"sku":"amicusrx-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/amicusrx-pestle-analysis.png?v=1772234296","url":"https:\/\/growthsharematrix.com\/products\/amicusrx-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}